Yarrow Bioscience, Inc.
YARW · XNASCIK 1566044fmd_0XS6FA929HJ000PG5J0TDEKJCXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 5 | 4 | 0 | – | 1 | 0 | 0 | 1 | 1 |
| Cost of revenue | – | – | 0 | 0 | 1 | 3 | – | – | – | – |
| Gross profit | – | – | 4 | 0 | – | (2) | – | – | – | – |
| Research and development | 11 | 29 | 64 | 51 | 44 | 20 | 18 | 16 | 31 | 19 |
| Selling, general and administrative | – | – | 14 | 45 | 90 | 20 | 16 | – | – | – |
| Total operating expenses | 15 | 34 | 65 | 76 | – | – | – | – | – | – |
| Operating income | (14) | (30) | (75) | (96) | (253) | (39) | (34) | (29) | (44) | (30) |
| Interest expense | – | – | 0 | 1 | 4 | 6 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 1 | (1) | (1) | 1 | (0) | 0 | 1 | 4 | 3 |
| Income before taxes | – | – | (74) | (95) | (256) | (45) | (34) | (28) | (40) | (27) |
| Income tax expense | – | 0 | 0 | (0) | (0) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (74) | (95) | (256) | (44) | (34) | (28) | (40) | (27) |
| Net income | (14) | (29) | (74) | (95) | (256) | (73) | (23) | (28) | (40) | (26) |
| Net income to common shareholders | (14) | (29) | (51) | (74) | – | – | – | – | – | – |